Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.51 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374753 | 0.78 | MMP8 (0.42) | MCL1MMP13PGR | |
| SCHEMBL3376339 | 0.76 | PTGES (0.58) | MCL1PTPN22NR3C1PTGESALOX5 | |
| SCHEMBL13337357 | 0.76 | NR3C1 (0.56) | MCL1PTPN22NR3C1PTGESALOX5 | |
| SCHEMBL3379996 | 0.73 | NR3C1 (0.58) | PTPN22NR3C1PTGESALOX5SMN1; SMN2 | |
| SCHEMBL3376558 | 0.72 | PTGES (0.46) | MCL1PTPN22NR3C1PTGESALOX5 | |
| SCHEMBL3377815 | 0.71 | PTGES (0.52) | MCL1PTPN22NR3C1PTGESALOX5 | |
| SCHEMBL3377212 | 0.69 | SMN1; SMN2 (0.71) | MMP9SMN1; SMN2MMP2 | |
| SCHEMBL3374719 | 0.68 | NR3C1 (0.42) | MCL1PTPN22NR3C1PTGESALOX5 | |
| SCHEMBL13337354 | 0.67 | SMN1; SMN2 (0.51) | NR3C1MMP9SMN1; SMN2MMP2 | |
| SCHEMBL18392320 | 0.67 | MCL1 (1.00) | MCL1NR3C1PTGESALOX5MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | MCL1 3270/4885PTPN22 2421/4885NR3C1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.